OpGen is uniquely positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks. Using its large and ever-growing Acuitas Lighthouse® Database of pathogens from around the world, the Company is developing disruptive technologies aimed to shift the paradigm for managing infectious diseases.Through its CLIA-certified clinical laboratory services, OpGen provides rapid detection and analysis of antibiotic resistance and high-resolution microbial sequence analysis. The Company's FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.